Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors.
Automated personalized GBM organoid drug screening platform.
- Authors / organisation
- Jungwirth G et al.
- Venue
- NPJ precision oncology
- Date
- 2026-06-16
- Type
- paper
- Year
- 2026
- DOI
- 10.1038/s41698-026-01552-5
- PMID
- 42303761
- Verification
- Europe PMC
Cited by GlioState topics
- Perturbation data for glioblastoma: radiotherapy, drugs and CRISPR (Perturbations)
- Therapy-induced plasticity in glioblastoma (Transitions)
Entities mentioned
- Patient-derived GBM organoids Models
- Glioblastoma Diseases
- Organoid drug screening Methods & concepts